Why the study?
Does ex vivo measurement and an APTT ratio using baseline APTT provide a better representation of plasma heparin levels compared to in vitro standardization in patients on heparin therapy?
Does ex vivo measurement and an APTT ratio using baseline APTT provide a better representation of plasma heparin levels compared to in vitro standardization in patients on heparin therapy?
In vitro APTT curves are inappropriate for heparin monitoring, and using an APTT ratio based on the patient's baseline APTT provides a more accurate representation of plasma heparin levels.
Patient baseline APTT ratio better represented heparin levels than in vitro curves; hypothesis-generating for monitoring, requires prospective validation before practice change.
Twenty patients were studied prospectively during heparin therapy. Three activated partial thromboplastin time (APTT) reagents were used to compare APTT values with plasma heparin levels during induction of heparin and transition of heparin to coumadin. A heparin in vitro dose APTT response curve and a heparin ex vivo curve were established. The in vitro sensitivity curves using different reagents were varied at therapeutic heparin levels. In contrast, the APTT reagents did not differ ex vivo. The in vitro curves demonstrated poor performance. Sixty percent of the patients did not adequately compare by APTT estimation of plasma heparin levels. An APTT ratio (1.5 to 2.5) using the patient's baseline APTT as the denominator demonstrated better representation of heparin levels. The in vitro APTT curves are inappropriate for heparin monitoring.
No takes yet. Share an insight, caveat, or question.
Sal J. Scialla (1985) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: